The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has shown that hospitalised COVID-19 patients have a reduced risk of death when given tocilizumab, an intravenous anti-inflammatory treatment for rheumatoid arthritis. The study also showed that this drug can not only shorten the time patients spend in the hospital before they are successfully discharged, but also reduce the need for a mechanical ventilator.